Free Trial

Biora Therapeutics Q1 2023 Earnings Report

Biora Therapeutics logo
$0.16 -0.03 (-14.21%)
As of 01/17/2025

Biora Therapeutics EPS Results

Actual EPS
-$15.90
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biora Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biora Therapeutics Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Biora Therapeutics Earnings Headlines

Firm Retention Summary: Biora Therapeutics
Biora Therapeutics undertakes Chapter 11 sales process
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
See More Biora Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biora Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biora Therapeutics and other key companies, straight to your email.

About Biora Therapeutics

Biora Therapeutics (NASDAQ:BIOR), a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

View Biora Therapeutics Profile

More Earnings Resources from MarketBeat